It has been shown that Benz improves Parkinson’s symptoms, mainly as a muscarinic M1 antagonist, as well as a DRI, which blocks the action of the DAT/SLC6A3 [24], while Benz also has affinities with other membrane proteins, including dopamine receptors, histamine receptors, and NET [25,26]. Here, SLC6A2 is linked to Parkinsonism.